Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilvegostomig + Bevacizumab +/- Tremelimumab vs Atezolizumab + Bevacizumab in 1L Advanced HCC
NCT06921785Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Mar 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of rilvegostomig in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall Survival at 6 years. Started May 2025; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06921785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06921785.